Question explored with the scientific record
Conversation so far
Answered on this page ↓
Ss31
Ss31 is almost certainly elamipretide, a mitochondria-targeted peptide studied for rare eye and muscle diseases. Nothing in this evidence shows it supports immunity or fights colds or flu.
The name matches elamipretide (SS31), a peptide aimed at mitochondria, the cell's power plants [5]. In aging mice it slowed and partly reversed vision decline, and eye drops worked about as well as injections [5]. That is a mouse study. It says nothing about immune support, and nothing about colds or flu.
The rest of the retrieved records are about other peptides entirely: influenza peptide vaccines in chickens [2], peptide-based diagnostic tests for H5N1 antibodies [3], and peptide inhibitors of viral fusion in cells [4]. None tested Ss31 in people for immune support. The one human-adjacent record is a peptide microarray that mapped antibody patterns after H1N1 infection versus vaccination [1], which is a diagnostic tool, not a supplement.
| What was tested | Model | Immune or cold/flu outcome |
|---|---|---|
| Elamipretide (SS31) [5] | Aging mice | Vision only; no immune endpoint |
| Replikin flu peptide vaccine [2] | Chickens | Reduced virus detection in vaccinated birds |
| H5N1 peptide ELISA [3] | Human sera | Diagnostic, not treatment |
| Fusion-inhibitor peptides [4] | Cells | Antiviral in vitro only |
If a seller is marketing "Ss31" for immune support, the burden is on them to show a human trial with a real outcome. No such trial appears here. The mouse vision work does not transfer to immunity, and the name similarity to other peptides is not evidence.
My call: Ss31 has no demonstrated role in immune support or cold/flu protection in humans; the only direct record is a mouse vision study. Confidence: moderate, because the retrieval is thin on Ss31 specifically.
Sources used 5
-
H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix ® vaccination
A peptide microarray covering the 2009 H1N1 proteome distinguished serum IgG epitope footprints between PCR-confirmed H1N1 infection and Pandemrix vaccination in a Swedish cohort, revealing exclusive vaccine-associated recognition of the HA epitope VEPGDKITFEATGNL.
DOI: 10.1111/imm.12448 -
Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus
This study evaluates the efficacy of a synthetic replikin peptide vaccine against the low-pathogenicity avian influenza H5 virus in chickens, demonstrating its potential to protect against infection and reduce virus shedding.
DOI: 10.1637/8892-042509-resnote.1 -
H5N1-SeroDetect EIA and Rapid Test: a Novel Differential Diagnostic Assay for Serodiagnosis of H5N1 Infections and Surveillance
Conserved H5N1 epitopes PB1-F2, M2e, and HA2 enable a peptide-based ELISA and rapid test (H5N1-SeroDetect) that accurately distinguishes H5N1 infection from seasonal influenza and vaccination, supporting large-scale, long-term surveillance.
DOI: 10.1128/jvi.06023-11 -
Peptide Inhibitors of Viral Membrane Fusion
Peptide inhibitors derived from viral fusion proteins can block membrane fusion and infection by lipid-enveloped viruses, with cholesterol or lipid conjugation often enhancing potency, though T-20 is the only clinically approved inhibitor.
DOI: 10.18103/mra.v8i9.2244 -
Treatment of age-related visual impairment with a peptide acting on mitochondria
Elamipretide (SS31), a mitochondria-targeted peptide, prevents and reverses age-related decline in photopic spatial vision in aging mice, with benefits preserved after withdrawal and effective via both systemic and ocular administration.
DOI: 10.1242/dmm.048256